Evidence-based·Last reviewed May 30, 2026·How we grade evidence

Vitamin B3

Vitamin

Useful mainly for correcting niacin deficiency (pellagra); niacinamide for non-melanoma skin cancer risk reduction.

Quick decision guide

May help most

correcting niacin deficiency (pellagra); niacinamide for non-melanoma skin cancer risk reduction

Common dosing range

14–16 mg NE/day (RDA); higher forms for specific uses under guidance

When to expect effects

Days (deficiency) to months (skin cancer prevention)

Watch out for

high-dose niacin causes flushing and can harm the liver; lipid use lacks outcome benefit

What is it

Vitamin B3 is a water-soluble B-vitamin that exists in several forms: niacin (nicotinic acid), niacinamide (nicotinamide), and nicotinamide riboside. All function as precursors to the coenzymes NAD+ and NADP+, which drive hundreds of redox reactions in cellular metabolism.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if

you have or are at risk of niacin deficiency
you have recurrent non-melanoma skin cancers (niacinamide)
you need a basic B-vitamin for metabolic support

Probably skip if

you want high-dose niacin for heart-disease prevention
you have liver disease, gout, or uncontrolled diabetes
you are pregnant and considering above-RDA doses

Evidence at a glance

pellagra (niacin deficiency)

Strong Evidence
Effect
Corrective and often rapid
Best fit
people with niacin deficiency or pellagra
Time
Days

non-melanoma skin cancer prevention

Good Evidence
Effect
~23% fewer new lesions in high-risk patients
Best fit
people with a history of multiple basal or squamous cell skin cancers
Time
Months

dyslipidemia (lipid lowering)

Limited Evidence
Effect
Meaningful changes in LDL, HDL, triglycerides
Best fit
people whose clinician targets specific lipid biomarkers
Time
Weeks

acne (topical niacinamide)

Limited Evidence
Effect
Modest
Best fit
people with mild inflammatory acne using topical niacinamide
Time
Weeks

Evidence for 4 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

pellagra (niacin deficiency)

Corrects deficiency
Strong Evidence

Niacin reliably reverses pellagra, the disease of niacin deficiency marked by dermatitis, diarrhea, and dementia. This is an established deficiency correction rather than a supplemental benefit. Response to repletion is typically rapid.

Effect size
Corrective and often rapid
Time to effect
Days
Best fit
people with niacin deficiency or pellagra
Less likely
well-nourished people without deficiency

Bottom line: Definitive treatment for niacin deficiency and pellagra.

non-melanoma skin cancer prevention

Supplement benefit
Good Evidence

A randomized controlled trial found oral niacinamide 500 mg twice daily reduced new non-melanoma skin cancers in high-risk patients over 12 months. The effect was modest and did not persist after stopping. Evidence is largely from this population, so generalization to average-risk people is uncertain.

Effect size
~23% fewer new lesions in high-risk patients
Time to effect
Months
Best fit
people with a history of multiple basal or squamous cell skin cancers
Less likely
people at average skin-cancer risk

Bottom line: Niacinamide modestly lowers new non-melanoma skin cancers in high-risk patients while taken.

dyslipidemia (lipid lowering)

Biomarker support
Limited Evidence

Pharmacological-dose niacin changes lipid biomarkers, lowering LDL and triglycerides and raising HDL via GPR109A activation. However, large outcome trials adding niacin to statins did not reduce cardiovascular events and showed added harms. This is therefore a biomarker effect, not a demonstrated clinical benefit.

Effect size
Meaningful changes in LDL, HDL, triglycerides
Time to effect
Weeks
Best fit
people whose clinician targets specific lipid biomarkers
Less likely
people seeking to prevent cardiovascular events

Bottom line: Niacin shifts lipid numbers but has not reduced cardiovascular events in trials, so the benefit is biomarker-level only.

Evidence is mixed

Niacin improves lipid biomarkers, but major RCTs adding it to statins found no cardiovascular-event benefit and increased adverse effects.

acne (topical niacinamide)

Supplement benefit
Limited Evidence

Topical niacinamide has shown modest improvement in inflammatory acne in small studies, likely via anti-inflammatory and sebum-related effects. Evidence is limited and often involves combination formulations. It is a reasonable, low-risk topical option rather than a primary therapy.

Effect size
Modest
Time to effect
Weeks
Best fit
people with mild inflammatory acne using topical niacinamide

Bottom line: Topical niacinamide may modestly help mild acne, but evidence is limited.

How it works

Once absorbed, vitamin B3 is converted into nicotinamide adenine dinucleotide (NAD+) and its phosphorylated form NADP+. These coenzymes are essential for ATP production from carbohydrates, fats, and protein, and they serve as substrates for sirtuins and PARP enzymes that govern DNA repair, gene expression, and cellular aging. Niacin (the acid form) at pharmacological doses also activates the GPR109A receptor on adipocytes, inhibiting fat breakdown and triggering the characteristic "niacin flush" through prostaglandin release. This receptor-mediated activity is unique to niacin and underlies its lipid-modifying effects. Niacinamide lacks the flushing and lipid-lowering effects but provides equivalent NAD+ support. The body can also synthesize a small amount of niacin from the amino acid tryptophan, with about 60 mg of tryptophan yielding 1 mg of niacin equivalent.

How to take it

1. Typical dose
RDA 14–16 mg NE/day; 20–100 mg for general support
2. Higher studied dose
500 mg twice daily niacinamide for skin cancer prevention; 1–3 g/day niacin for lipids (physician-supervised)
3. Timing
any time; immediate-release niacin not close to bedtime if flushing disrupts sleep
4. With food
take flushing niacin with food and a full glass of water; niacinamide can be taken without food
5. How long to try
deficiency: until corrected; skin cancer prevention: ongoing under guidance

What to track

flushing and itching
liver enzymes and uric acid at high doses
blood glucose at high doses
new skin lesions

4 commercial forms

Compare the main delivery options and what they’re best suited for.

Niacin (nicotinic acid)

Immediate-release niacin produces the most flushing but has the cleanest safety profile at therapeutic doses. Used for cholesterol modification under medical supervision.

Causes the characteristic flush; the only form with strong lipid effects.

Niacinamide (nicotinamide)

Preferred for general B3 supplementation and indications outside lipids. Does not lower cholesterol but is well-tolerated at higher doses.

No flushing; equivalent NAD+ support.

Inositol hexanicotinate ("no-flush niacin")

Marketed as flush-free niacin, but it appears to release very little active niacin and does not reliably improve lipids.

Slowly hydrolyzes to release free niacin; lipid-lowering evidence is weak.

Sustained/extended-release niacin

Prescription forms (e.g., Niaspan) are designed for cholesterol indications. Over-the-counter sustained-release products carry meaningful liver risk.

Reduced flushing but higher hepatotoxicity risk than immediate-release.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

flushing, itching, and warmth with niacin above 35 mgGI upset

Serious risks

  • hepatotoxicity with high-dose or slow-release niacin

  • elevated uric acid and gout flares

  • worsened glucose tolerance at high doses

Who should avoid it

  • people with liver disease, active peptic ulcer, gout, or uncontrolled diabetes (high-dose niacin)
  • people with G6PD deficiency (high-dose niacin)

Pregnancy & breastfeeding

Stay within RDA amounts in pregnancy and lactation unless directed by a clinician.

Interactions

statinsModerate

increased risk of myopathy

blood-pressure medicationsModerate

niacin may potentiate blood-pressure lowering

diabetes medicationsModerate

niacin can raise blood glucose, requiring dose adjustment

alcoholMinor

amplifies flushing and liver stress

Protocols featuring Vitamin B3

Evidence-backed routines where Vitamin B3 plays a role.

NAD+ & Cellular Energy

longevity

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for mitochondrial energy production, DNA repair (via sirtuins and PARPs), and cellular signaling. NAD+ levels decline measurably with age — roughly 50% by middle age in some tissues. The 2020s have seen explosive interest in NAD+ precursors (NMN, NR) as longevity interventions, popularized by researchers like David Sinclair. The honest framing: NAD+ precursors RELIABLY raise blood NAD+ levels in human trials. What''s less clear is whether this translates to meaningful longevity, cognitive, or healthspan endpoints in humans — most positive evidence is from animal models or small short-duration human trials. This stack is for adults interested in cellular energy support, especially over 40 — with the explicit caveat that this is experimental territory relative to the rest of the library. Foundational Longevity remains the better starting point for general healthspan; this protocol is for adults who want to specifically explore the NAD+ pathway.

Cholesterol Support

cardiovascular

Elevated LDL-C and ApoB are causal drivers of cardiovascular disease — the leading killer of adults. Statins are the gold-standard pharmaceutical intervention with the strongest trial evidence ever assembled in medicine. This stack is NOT a substitute for statin therapy when one is indicated by your cardiovascular risk profile. It IS useful as: a complement to statins for additional LDL reduction, an option for statin-intolerant adults, or a preventive layer for adults with borderline lipids who want to reduce risk before pharmaceutical intervention is warranted. Red yeast rice is essentially low-dose lovastatin (a natural statin compound) and carries similar precautions; bergamot, plant sterols, and niacin each have independent LDL-lowering evidence with different mechanisms. If your LDL-C is over 160 mg/dL, you have a family history of premature cardiovascular disease, or you have other risk factors, please see your doctor. ApoB is a better predictor than LDL-C alone; ask for it.

Rosacea Support

skin conditions

Rosacea is a chronic inflammatory facial dermatosis affecting roughly 5% of adults — disproportionately women aged 30-60 with fair skin (Fitzpatrick I-II), though it occurs across all skin types and is frequently underdiagnosed in darker skin. It presents as four overlapping phenotypes: erythematotelangiectatic (persistent central facial redness with visible vessels), papulopustular (acne-like inflammatory papules and pustules), phymatous (skin thickening and tissue overgrowth, most often on the nose), and ocular (dry, gritty, inflamed eyes — frequently missed because patients see ophthalmology and dermatology separately). The pathology is multifactorial: dysregulated innate immunity via the cathelicidin/LL-37 pathway, mast cell activation, neurovascular hyperresponsiveness, and Demodex folliculorum mite overgrowth all interact. The first-line conventional toolkit — topical metronidazole, ivermectin (Soolantra), azelaic acid, and brimonidine; oral sub-microbial doxycycline; isotretinoin for refractory phymatous disease — is genuinely effective and should not be skipped in favor of supplements. Supplements occupy a narrower supportive role here than in eczema or psoriasis. The trial evidence is thinner, and the most impactful daily actions are trigger identification, photoprotection, and gentle skincare — not a pill regimen. We've included supplements with at least some direct rosacea evidence (oral zinc, niacinamide) plus a few with strong mechanistic rationale (omega-3 for ocular subtype, quercetin for mast cell stabilization). If your rosacea is moderate-to-severe, scarring, or involves the eyes, see a dermatologist (and an ophthalmologist for ocular involvement) — topical ivermectin and oral doxycycline transformed outcomes in the last decade and remain the backbone of treatment.

Food sources

Chicken breast (3 oz, cooked)

Amount
10.3 mg
%DV

Beef liver (3 oz, cooked)

Amount
14.9 mg
%DV

Tuna (3 oz, cooked)

Amount
8.6 mg
%DV

Turkey (3 oz, cooked)

Amount
10 mg
%DV

Salmon (3 oz, cooked)

Amount
8.6 mg
%DV

Peanuts (1 oz, dry roasted)

Amount
4.2 mg
%DV

Brown rice (1 cup, cooked)

Amount
5.2 mg
%DV

Fortified breakfast cereals

Amount
5-20 mg per serving
%DV

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for

form clearly stated (niacin vs niacinamide)
flush-free options labeled (niacinamide, inositol hexanicotinate)
appropriate dose for the intended use

Be skeptical of

prevents heart attacks
no liver risk at high doses
megadose detox

Frequently asked questions

Why does niacin make me flush?

Niacin (nicotinic acid) activates a receptor in the skin that triggers prostaglandin release, dilating blood vessels and causing warmth, redness, and tingling. The flush typically peaks in 15-30 minutes and fades within an hour.

What's the difference between niacin and niacinamide?

Both raise NAD+ and prevent deficiency. Only niacin (nicotinic acid) causes flushing and lowers cholesterol. Niacinamide is flush-free but does not affect lipids.

Is no-flush niacin effective for cholesterol?

Inositol hexanicotinate, sold as no-flush niacin, releases very little active niacin and does not reliably lower cholesterol. For lipid effects, immediate-release niacin or a prescription form is needed.

Can I take high-dose niacin without my doctor knowing?

Not recommended. Doses above 500 mg can cause liver issues, raise blood sugar, and interact with statins. Have liver enzymes and glucose monitored if using high doses.

Does niacinamide help with skin?

Topical niacinamide is well-studied for acne, redness, and skin barrier function. Oral nicotinamide has evidence for reducing recurrence of non-melanoma skin cancers in high-risk patients.

References by claim

pellagra (niacin deficiency)

Redzic et al., 2026PubMed (2026) link

Mousa et al., 2026PubMed (2026) link

non-melanoma skin cancer prevention

Mainville et al., 2022PMC (2022) link

Chen et al., 2015PubMed (2015) link

dyslipidemia (lipid lowering)

Ding et al., 2015PubMed (2015) link

Boden et al., 2011PubMed (2011) link

acne (topical niacinamide)

Draelos et al., 2006PubMed (2006) link

Kozan et al., 2020PubMed (2020) link

Track Vitamin B3 with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.